Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

73.80 -1.31 (-1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DexCom, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
25 26 Next >
2 Medical Device Stocks to Buy Hand Over Fist in March
Don't let their modest gains over the past year mislead you; these stocks can make for great long-term investments. 
Via The Motley Fool
Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named SL Green Realty Corp. 
Via Benzinga
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant... 
Via Benzinga
Exposures Product Safety
Stocks Surge, Gold Hits New All-Time High, Bitcoin Reclaims $67,000 As Powell Reassures Wall Street: What's Driving Markets Wednesday?
Markets rallied across the board on Wednesday, erasing the uptick in volatility seen in the previous session, following reassurances from Fed Chair Jerome Powell regarding the Fed’s willingness to ease... 
Via Benzinga
Topics Economy
Exposures Interest Rates
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
Here's How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription
FDA-approved Dexcom Stelo: Over-the-counter glucose monitoring for non-insulin users. Stelo, the first OTC CGM, available online without prescription from summer 2024. Continuous glucose tracking with... 
Via Benzinga
Exposures Product Safety
Campbell Soup, Box And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading mostly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Adding $1,000 to These Top Growth Stocks Would Be a Brilliant Move
With patience, these stocks will provide outsized returns to investors. 
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
DexCom: Q4 Earnings Insights
Via Benzinga
Prediction: 2 Stocks That Could Trounce the Market
They have done it before. 
Via The Motley Fool
3 Telehealth Stocks With Room to Run in 2024
Embrace 2024's leading telehealth stocks to buy, merging cutting-edge care with smart investing for a lucrative portfolio. 
Via InvestorPlace
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
Got $1,000? Buy These Hot Growth Stocks Before They Take Off
If you have just $1,000 to spare, you can scoop up shares of these growth stocks before their prices explode. 
Via The Motley Fool
Xylem, DexCom And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by around 0.4% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $13,000 Today
Via Benzinga
NASDAQ:DXCM: a strong growth stock preparing for the next leg up?.
DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Evaluating NASDAQ:DXCM for Growth Investment Opportunities.
Why the growth investor may take a look at NASDAQ:DXCM. 
Via Chartmill
These 2 Growth Stocks Could Soar 33% and 45% According to Wall Street Analysts. Are They Smart Buys Now?
Expectations are high for companies making blood sugar monitors and business automation software. 
Via The Motley Fool
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Companies in the healthcare industry tend to generate returns in a wide range of market environments. 
Via The Motley Fool
Continuous Glucose Monitor Maker Dexcom's Q4 Profit Triples On Volume Growth And New Customer Additions
Dexcom's Q4 2023 performance, reporting $1.03 billion sales, $256.3 million profits, and beating estimates. Dexcom projects $4.15-$4.35 billion in 2024 revenues. William Blair affirms Outperform... 
Via Benzinga
DexCom (DXCM) Q4 2023 Earnings Call Transcript
DXCM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
2 Phenomenal Stocks to Buy for the New Year
These growth stocks are raking in profits and cash as leaders in their respective industries. 
Via The Motley Fool
Stryker Stock Sees Relative Strength Rating Jump To 84
The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84. 
Via Investor's Business Daily
These 2 Growth Stocks Are Brilliant Buys for the New Year
Business is booming for these stocks, and investors might want to stop and take note. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.